Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age (SORAML)

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00893373
First received: May 4, 2009
Last updated: February 2, 2012
Last verified: February 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
No publications provided by Technische Universität Dresden

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):